Home > Kliniken und Institute > Dermatologie > Forschung > Klinische Studien
Klinik und Poliklinik für Dermatologie

Klinische Studien

FOCUS PHP-OCM-301 Studie:  A randomized, controlled, Phase III Study to evaluate the efficancy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic.dominant ocular melanoma

ADMEC-O:  Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observation

Illuminate 2125- MEL-301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

BMS CA045-001:  A Phase 3, Randomized, open label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma

ADO-Register: Prospektives Online- Register zur Versorgungsforschung in der dermatologischen Onkologie

Novartis COMBI-r:  Nicht-interventionelle Studie bei Patienten mit fortgeschrittenem Melanom zur Bewertung der Kombinationstherapie mit Dabrafenib und Trametinib in der klinischen Routine

Roche CoveNIS: A non-interventional study to investigate the effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with and without brain metastasis with BRAF V600 mutant melanoma under real world conditions

BMS CheckMate234 NivoPass: Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practise

BMS NIS-NICO: Eine nationale, prospektive, nicht-interventionelle Studie (NIS) zu Nivolumab-Monotherapie oder in Kombination mit Ipilimumab bei Patienten mit fortgeschrittenem (inoperablem oder metastasiertem) Melanom

Roche NIELS: Nicht-interventionelle Studie zur Untersuchung der Effizienz, Sicherheit und Verwendung von Vismodegib bei lokal fortgeschrittenem Basalzellkarzinom unter realen Bedingungen

Dynavax DV3-MEL-01:  A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Enrollment closed

Combi AD BRF115532: A phase III randomized double blind study of dabrafenib in Combination with trametinib versus two placebos in the Adjuvant treatment of High-Risk BRAF V600 mutation-positive melanoma after surgical resection

Enrollment closed

Novartis COMBI-I: A randomized, double-blind, placebo-controlled, phase III studycomparing the combination of PDR001,dabrafenib and trametinib versus placebo,dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAFV600 mutant melanoma  

Enrollment closed

Roche Trilogy Studie CO39262: A phase III, double-blinded, randomized, placebo-controlled study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated brafv600 mutation−positive patients with unresectable locally advanced or metastatic melanoma

Enrollment closed

AMGEN Masterkey265: A Phase 1b/3, Multicenter, Trial of Talimogene laherparepvec in Combination with Pembrolizumab for Treatment of Melanoma

Enrollment closed

BMS CheckMate 209-401: A single-arm, open-label, multicenter clinical trial of Nivolumab (BMS-936558) combined with Ipilimumab followed by Nivolumab Monotherapy as first-line therapy for subjects with histologically confirmed stage III (Unresectable) or stage IV melanoma

Enrollment closed

IMMUNED: A phase II randomized, double-blind trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus double-placebo control as a post surgical/post radiation treatment for stage IV melanoma with no evidence of disease.

Enrollment closed

Columbus CMEK162B2301: A 2-part phase III radomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma

Enrollment closed

© Universitätsklinikum Regensburg | Impressum | Datenschutz
Letzte Aktualisierung: 06.04.2020 | Online-Redaktion
Patienten/Besucher
Einweiser
Studierende
Wissenschaftler
Über uns
Beruf und Karriere
Universität Regensburg
Facebook
Twitter
Youtube